Who answers in China for a drug held by a foreign company
The entity in China that a foreign drug holder must designate, the conditions it must meet from 1 July 2025, and the liability it shares.
21 posts
The entity in China that a foreign drug holder must designate, the conditions it must meet from 1 July 2025, and the liability it shares.
How INDs, NDAs, ANDAs and biologics license applications are built under 21 CFR Parts 312, 314 and 601, and how FDA reviews them.
How Directive 2001/83/EC governs the manufacture and import of medicinal products in the EU, from manufacturing authorisation through to batch certification.
What EU law requires of marketing authorisation holders after authorisation, from adverse reaction reporting and PSURs to additional monitoring.
How CGMP under 21 CFR Parts 210 and 211 applies to drugs and biologics, covering the phase 1 exemption, quality control unit duties and records.
The conditions on which China accepts clinical trial data produced abroad for a drug registration, and when further trials in China are required.
How FDA post-approval duties work for drugs and biologics, covering adverse experience reports, annual and distribution reports, changes and supply notices.
How EU medicines reach the market: the centralised Union route, national authorisation, mutual recognition and decentralised procedures, with their timelines and evidence.
How Directive 2001/83/EC governs outer packaging, immediate packaging and package leaflet content for medicines in the EU, and what claims are barred.
How the NDA, 505(b)(2), ANDA and BLA routes work under 21 CFR Parts 314 and 601 and what evidence each requires.
Which drugs China buys through national volume-based procurement, who must take part, and how payment and use of the selected drugs are secured.
How 21 CFR Parts 201 and 202 govern drug and biologic labels, prescribing information, Drug Facts panels and permitted claims in advertising.
How Directive 2001/83/EC sets the evidence for a marketing authorisation, covering full dossiers and the generic, biosimilar and well-established use routes.
How Regulation (EU) No 536/2014 governs clinical trials of medicinal products, from authorisation through the EU portal to informed consent.
The periods Chinese law sets for each step of drug registration, what extends them, and the 30-working-day channel for innovative drug trials.
How FDA evidence standards work for NDAs, 505(b)(2) applications, ANDAs and biologics licenses, including accelerated approval and the animal rule.
The port filing, the customs clearance form and the testing that apply to a drug imported into China, with the periods for registration testing.
When an IND is required under 21 CFR Part 312, the exemptions, and the informed consent and investigator duties that govern FDA-regulated drug trials.
Breakthrough therapy, conditional approval, priority review and special approval for drugs in China, and which of them shortens a review period.
How a drug clinical trial is cleared in China, from the 60-working-day rule and the 30-working-day channel to the filings that replace approval.
What China's commercial health insurance innovative drug list is, which drugs may apply to it, and what a place on the list gives.